|
No. | Age (yrs), sex (M/F), anatomic sites | Systemic therapy in metastatic disease | ISTH score | DIC in 1st 30 days∧ | DIC resolved with disease response/ stability | DIC recurred at progression | Bone marrow involvement | Tumor burden@ | Clinical thrombosis/ hemorrhage | Survival in metastatic disease | Remarks |
|
1 | 37 M liver with metastasis to spleen | Pegylated liposomal doxorubicin | 7 | Yes | Yes | Yes | No | Nonbulky | No | 9 months | Metastatic at first presentation. No evidence of clinically significant portal hypertension |
|
2 | 42 F breast (de novo) with metastasis to chest wall, ribs, lung | Pegylated liposomal doxorubicin plus carboplatin, sirolimus, pazopanib, abraxane, bevacizumab plus vinorelbine | 5 | No | NA | Yes | Not done | Nonbulky | Yes | 11 months | Localized to right breast at first presentation, had mastectomy, then 6 cycles adjuvant gemcitabine plus docetaxel followed by radiation. Developed metastatic relapse within 11 months |
|
3 | 39 M mediastinal with metastasis to bone, lung, brain | Doxorubicin plus paclitaxel, ifosfamide plus cisplatin, gemcitabine plus vinorelbine | 5 | Yes | Yes | Yes | Not done | Bulky | Yes | 5 months | Metastatic at first presentation |
|
4 | 54 F cardiac with metastasis to lung, pleura, bones, bone marrow | Doxorubicin plus ifosfamide | 7 | Yes | Yes | Yes | Yes | Bulky | Yes | 6 months | Metastatic at first presentation |
|
5 | 70 F breast (radiation related) with metastasis to lymph nodes, lung | Doxorubicin plus ifosfamide | 6 | Yes | Yes | Yes | No | Nonbulky | No | 11 months | Metastatic at first presentation; developed angiosarcoma 9 years following lumpectomy and radiation for early stage breast adenocarcinoma |
|
6 | 66 F skull and meninges with metastasis to spinal cord, lungs, bone | Nil | 6 | Yes | NA | NA | Not done | Nonbulky | No | 1 month | Metastatic at first presentation; poor performance status precluded any therapy |
|
7 | 78 M foot (bony) with metastasis to lungs | Nil | 4* | Yes | NA | NA | Not done | Nonbulky | No | 2 months | Metastatic at first presentation; poor performance status precluded any therapy |
|